Cigar Companies Agree to Health Warnings on Products and Ads

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 8
Volume 9
Issue 8

WASHINGTON-The seven largest US cigar companies will place health warnings on their products and advertisements as the result of an agreement with the US Federal Trade Commission. The warnings read: “Cigar smoking can cause cancers of the mouth and throat, even if you do not inhale.” “Cigar smoking can cause lung cancer and heart disease.” “Tobacco use increases the risk of infertility, stillbirth, and low birth weight.” “Cigars are not a safe alternative to cigarettes.” “Tobacco smoke increases the risk of lung cancer and heart disease, even in nonsmokers.”

WASHINGTON—The seven largest US cigar companies will place health warnings on their products and advertisements as the result of an agreement with the US Federal Trade Commission. The warnings read: “Cigar smoking can cause cancers of the mouth and throat, even if you do not inhale.” “Cigar smoking can cause lung cancer and heart disease.” “Tobacco use increases the risk of infertility, stillbirth, and low birth weight.” “Cigars are not a safe alternative to cigarettes.” “Tobacco smoke increases the risk of lung cancer and heart disease, even in nonsmokers.”

Articles in this issue
Irinotecan Plus Cisplatin May Be a Promising Radiation Sensitizer, According to Phase II Study
Major Trial of Four Newest Chemotherapy Regimens for Advanced NSCLC Shows Comparable Survival
Irinotecan-Containing Chemotherapy Regimens Active in Pancreatic Cancer and Ovarian Cancer
Interim Results Show Similar Response Rates for TEC vs CEV in Small-Cell Lung Cancer
Scientists Identify Gene Mutations in Multiple Myeloma
Irinotecan Plus Cisplatin Results in Highly Significant Survival Improvement in Extensive-Disease Small-Cell Lung Cancer
New Analyses Establish the Addition of Irinotecan to Fluorouracil/Leucovorin as the New Standard of Care for First-Line Rx of Metastatic Colorectal Cancer
Single-Agent Herceptin Active in Metastatic Breast Cancer
Brain Metastases Respond to Paclitaxel, Carboplatin, and Brain RT
AC Comparable to CMF in ER-Negative, Node-Negative Early-Stage Breast Cancer
Herceptin/Vinorelbine Promising in Metastatic Breast Cancer
Early Phase III Results Indicate Concurrent Chemoradiation Is Promising for Treatment of Locally Advanced NSCLC
Gemcitabine/Vinorelbine Boosts Survival in Elderly NSCLC Patients
Timing Affects Chemotherapy’s Effectiveness and Tolerability in Metastatic Colon Cancer
Virtual Colonoscopy Promising for Colon Cancer Screening
Recent Videos
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content
One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups

Russ Conroy
October 31st 2025
Article

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

Caroline Seymour
October 26th 2025
Article

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.